These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30929977)

  • 1. Single-centre retrospective observational study comparing trough blood concentration and safety of teicoplanin formulations.
    Shinoda R; Shinoda Y; Ohashi K; Matsuoka T; Hirose T; Sugiyama T; Yoshimura T
    J Infect Chemother; 2019 Jul; 25(7):563-566. PubMed ID: 30929977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
    Byrne CJ; Egan S; Fennell JP; O'Byrne P; Enright H; Deasy E; Ryder SA; D'Arcy DM; McHugh J
    Int J Antimicrob Agents; 2015 Oct; 46(4):406-12. PubMed ID: 26228465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of teicoplanin concentrations and safety analysis in neonates.
    Yamada T; Kubota T; Nakamura M; Ochiai M; Yonezawa M; Yano T; Kawashiri T; Egashira N; Hara T; Masuda S
    Int J Antimicrob Agents; 2014 Nov; 44(5):458-62. PubMed ID: 25218156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.
    Matsumoto K; Kanazawa N; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2010 Jun; 16(3):193-9. PubMed ID: 20195882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Takai Y; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
    BMC Pharmacol Toxicol; 2020 Jul; 21(1):50. PubMed ID: 32641110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections.
    Wang T; Li N; Hu S; Xie J; Lei J; Wang Y; Zheng X; Xing J; Dong Y
    Int J Clin Pharmacol Ther; 2015 May; 53(5):356-62. PubMed ID: 25828639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients.
    Li H; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Zhang Y; Wang T; Shi Q
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):277-288. PubMed ID: 31608579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Doita A; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Ikeuchi H; Uchino M; Kimura T
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1501-9. PubMed ID: 27278654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
    Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
    J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Teicoplanin Trough Values After the Recommended Loading Dose in Children With Associated Safety Analysis.
    Yamada T; Kubota T; Yonezawa M; Nishio H; Kanno S; Yano T; Kobayashi D; Egashira N; Takada H; Hara T; Masuda S
    Pediatr Infect Dis J; 2017 Apr; 36(4):398-400. PubMed ID: 27977550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study.
    Roberts JA; Stove V; De Waele JJ; Sipinkoski B; McWhinney B; Ungerer JP; Akova M; Bassetti M; Dimopoulos G; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J;
    Int J Antimicrob Agents; 2014 May; 43(5):423-30. PubMed ID: 24630304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration.
    Rossi A; Buttini F; Colombo P; Mor M; Pala D; Bortolotti F; Colombo G
    Int J Pharm; 2013 Jul; 451(1-2):50-6. PubMed ID: 23628401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.
    Spence MM; Nguyen LM; Hui RL; Chan J
    Pharmacotherapy; 2012 Nov; 32(11):981-7. PubMed ID: 23074134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased teicoplanin doses are associated with improved serum levels but not drug toxicity.
    Matthews PC; Chue AL; Wyllie D; Barnett A; Isinkaye T; Jefferies L; Lovering A; Scarborough M
    J Infect; 2014 Jan; 68(1):43-9. PubMed ID: 24012820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy.
    Kim SH; Kang CI; Huh K; Cho SY; Chung DR; Lee SY; Kim YJ; Peck KR
    Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2113-2120. PubMed ID: 31372903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of initial loading procedure for teicoplanin in critically ill patients with severe infections.
    Matsumoto K; Kanazawa N; Watanabe E; Yokoyama Y; Fukamizu T; Shimodozono Y; Maeda C; Yasuda T; Kakihana Y; Ikawa K; Morikawa N; Takeda Y
    Biol Pharm Bull; 2013; 36(6):1024-6. PubMed ID: 23727923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective study of teicoplanin loading regimen that rapidly achieves target 15-30 μg/mL serum trough concentration.
    Kato H; Hamada Y; Hagihara M; Hirai J; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
    J Infect Chemother; 2016 May; 22(5):308-13. PubMed ID: 26960579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication.
    Kanazawa N; Matsumoto K; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2011 Apr; 17(2):297-300. PubMed ID: 20714913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.
    Sato M; Chida K; Suda T; Muramatsu H; Suzuki Y; Hashimoto H; Gemma H; Nakamura H
    J Infect Chemother; 2006 Aug; 12(4):185-9. PubMed ID: 16944256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis.
    Brink AJ; Richards GA; Lautenbach EE; Rapeport N; Schillack V; van Niekerk L; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jun; 45(6):647-51. PubMed ID: 25819167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.